Chris Chiozza (Brooklyn Nets) with an assist vs the Minnesota Timberwolves, 04/13/2021
Chris Chiozza (Brooklyn Nets) with an assist vs the Minnesota Timberwolves, 04/13/2021
Frontier Lithium Inc. (TSXV: FL) (OTCQX: LITOF) ("Frontier" or "the Company") and Reginald (Rick) Walker, Chair of the Board, are saddened to announce the passing of longtime Board Member, John G. Kelly.
While some Raptors fans may be considering OG Anunoby as a future No. 1 option, it's easy to underestimate how hard that transition is and how much Pascal Siakam has already flourished in that role.
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”), of the important May 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased BELLUS securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the BELLUS class action, go to http://www.rosenlegal.com/cases-register-2058.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose information that resulted in a scheme that: (1) deceived the investing public regarding BELLUS’s business, operations, drug products, drug product development, competition, and present and future business prospects; (2) facilitated the Company’s September 2019 public offering (“Offering”); (3) created artificial demand for the BELLUS common shares sold in the Offering; (4) enabled the Company to receive approximately $70 million in net proceeds from the sale of BELLUS common stock in the Offering; and (5) caused purchases of BELLUS publicly traded common stock at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the BELLUS class action, go to http://www.rosenlegal.com/cases-register-2058.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 email@example.com firstname.lastname@example.org email@example.com www.rosenlegal.com
(Bloomberg) -- Amazon.com Inc. is selling bonds to refinance debt and buy back stock, as cheap borrowing costs prove too tempting to resist even for a company with tens of billions of dollars in cash.The online retail giant is issuing $18.5 billion of debt in eight parts, according to people with knowledge of the matter. The longest portion, a 40-year security, will yield 95 basis points over Treasuries, after initially discussing around 115 basis points, said the people, who asked not to be identified because the details are private.Companies have been taking advantage of wide-open bond markets and spreads at three-year lows to score cheap borrowing, even if they don’t need it. With the economy rebounding from the pandemic, U.S. investment-grade firms are increasingly tempted to spend their cash cushions on acquisitions and dividend hikes, or borrow even more.Read more: Corporate Cash Grab Flashes Warning for Bonds: Lisa AbramowiczAt $18.5 billion, it’s Amazon’s biggest bond sale ever, and the second-largest this year behind Verizon Communication Inc.’s $25 billion offering in March. The company was said to originally be targeting $15 billion.Amazon is coming off of a record earnings quarter and it provided a sales forecast for the current period that was stronger than analysts’ estimates. Cash, cash equivalents and marketable securities stood at $73 billion at the end of March, near an all-time high.“They can grow into this leverage,” Matt Brill, head of North America investment grade at Invesco Ltd., said on Bloomberg TV Monday. “If you’re able to borrow for reasonably cheap, and then you’re able to get the operating leverage to go with it, it results in a lot of earnings.”A representative for Amazon did not immediately respond to requests for comment.What Bloomberg Intelligence Says“The size of Amazon.com’s balance sheet may grow meaningfully as its weighted-average-cost of debt capital hovers near zero. With abundant cash and growing free cash flow, borrowing may not be needed. Yet the ability to fund organic growth and potentially initiate a large shareholder-return program at historically low costs suggests additional debt over time.”-- Robert Schiffman, senior credit analyst. Click here to read the researchAmazon has been a fairly infrequent issuer, but it comes in big on those rare occasions. It last tapped the bond market in June 2020, borrowing $10 billion for general corporate purposes. Prior to that, it sold $16 billion of bonds in 2017 to help finance its acquisition of Whole Foods Market Inc.The proceeds of Monday’s offering will be for general corporate purposes, which may also include acquisitions and working capital. The two-year bond will be allocated for eligible green or social projects, which may include clean transportation, renewable energy and sustainable buildings, according to bond documents.Moody’s Investors Service upgraded Amazon one notch to A1, its fifth-highest investment-grade rating, with a stable outlook. While the new debt sale temporarily increases leverage, proceeds are expected to be deployed over time for capital expenditures that fuel growth, which is a long-term positive for the credit, said Moody’s analyst Charles O’Shea.Amazon has been on a spending spree since the pandemic began, building new warehouses and cloud-computing data centers across the world to meet surging demand from online shoppers and businesses turning to remote work. Purchases of property and equipment totaled $45 billion in the 12 months ended in March, up from $20 billion during the prior period.The company’s board of directors authorized $5 billion in share buybacks in 2016, but it has never made purchases under that authority.Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley and Wells Fargo & Co. are managing the sale.(Updates with deal size and pricing in the second paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Melinda Gates began divorce moves at time Bill’s meetings with Jeffrey Epstein revealedWife of world’s fourth-richest man explored options almost two years ago, roughly at time sex criminal Epstein died in jail Reports suggest that Bill Gates’s dealings with Jeffrey Epstein were one source of concern for his wife, Melinda. Photograph: Getty Images
We would like to announce that Pillars of Wellness is launching Canada’s first online rehab group program designed for individuals that have had a diagnosis or symptoms of COVID-19 and are experiencing ongoing symptoms and issues that limit their ability to return to their usual daily activities or employment duties.
The US has relaxed rules on fuel transport after a ransomware cyber-attack took the pipeline offline.
deGrom lasted five innings in his first start since returning from lat inflammation, and a day later he's headed to the IL.
The National Transportation Safety Board (NTSB) said testing showed Autopilot could not have been functioning in an April 17 Tesla Model S fatal crash near Houston, Texas because a key feature could not have been in use, according to a preliminary report released Monday. Local police have said they believed the crash occurred with no one in the driver's seat, raising questions about Tesla's driver assistance systems. The NTSB said the vehicle was equipped with "Autopilot" – Tesla’s advanced driver assistance system - and the system requires both Traffic Aware Cruise Control and Autosteer systems to be engaged.
Israel launches airstrikes on Gaza strip after Hamas rocket attacks Gaza health ministry says nine Palestinians were killed in Israeli strikes after Palestinian groups fired rockets into Israel Then scene in the northern Gaza Strip after Israeli airstrikes. The Gaza health ministry said nine Palestinians were killed. Photograph: Mohammed Salem/Reuters
Chubby raccoon Mark eats at the family dinner table, nicks the cat's food if he fancies it - and raids the fridge for his favourite shrimp treats.
The Capitol Police force was hobbled by inadequate intelligence gathering ahead of the Jan. 6 siege, a watchdog says in a new internal report, alarming lawmakers who are concerned for their own safety amid rising threats against members of Congress. Capitol Police Inspector General Michael Bolton will testify Monday in the first of three House hearings this week on what went wrong during the Jan. 6 insurrection. Many lawmakers are receiving threats and worry for their safety after the U.S. Capitol was so easily breached on Jan. 6 by supporters of then-President Donald Trump who wanted to overturn the election.
A strong second-quarter earnings report, as well as enthusiasm from Wall Street, lit up investors' excitement last month.
Hangzhou Safari Park denied the escape even after surveillance video caught one of the large cats roaming a nearby residential area.
Vicki Gunvalson announced her exit from the Bravo show in January 2020
(Bloomberg) -- California Governor Gavin Newsom said he plans to use a massive tax-collection windfall to help finance a massive $100 billion economic recovery package, with the centerpiece a proposal to give $11.9 billion of direct cash payments to most Californians.The plan would build on a previous program distributing $600 checks to qualifying low-income residents by expanding eligibility to the middle class. Two out of three Californians would receive a check of at least $600, with families with children receiving an additional $500. It would create the biggest state tax rebate on record, Newsom said Monday at a press conference in Oakland.“We believe people are better suited than we are to make determinations for themselves on how best to use these dollars,” Newsom said.The Democratic governor is seizing on an unprecedented $75 billion operating budget surplus, fueled by a surging economy and capital-gains taxes, to greatly expand the state’s role in the recovery just as he is facing a potential recall election later this year. The windfall leaves Newsom and lawmakers with $38 billion extra to spend as they see fit, since some of the money is already earmarked.The state will get an estimated $27 billion from President Joe Biden’s stimulus plan, according to latest Treasury figures.Newsom’s plan would also spend $5.2 billion on what he said would be the largest renter assistance package in the country and would allow low-income residents to cover their back-rent and their rent for several months into the future. It also spends $2 billion to cover overdue water and utility bills.Excess RevenueNewsom will spend the week highlighting parts of a package he billed the “California Comeback Plan.” He’s required to present a revised budget for the next fiscal year by the May 14 deadline.The announcement underscores the improved financial picture of the most-populous U.S. state, which last May girded for deficits because of the pandemic-spurred recession. But the state, with a progressive tax system that rakes in more revenue when the income of the highest earners rises, has collected more than it expected from its wealthiest residents. That group has reaped the benefits of rising stock prices and stable employment even as lower-income workers lost their jobs in the pandemic.The checks may satisfy a requirement being triggered for the first time since 1986 that excess revenue be returned to taxpayers. The voter-approved state appropriations limit is meant to keep inflation-adjusted per-person government spending under the 1979 level. Lawmakers are required to split excess revenue between taxpayer rebates and education funding.Newsom said the rebate mandate isn’t driving his proposal, but the $11.9 billion in cash payments to taxpayers earning less than $75,000 a year is more than is required to fulfill it.“The state is awash in cash,” John Ceffalio, senior municipal research analyst at CreditSights Inc, said before the announcement. “California came into the pandemic in good fiscal shape and it’s probably leaving it in even better fiscal shape.(Updates with surplus in third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Trading to Commence at Market Open on Tuesday May 11, 2021 Toronto, Ontario--(Newsfile Corp. - May 10, 2021) - Magna Mining Inc. (the "Company") is pleased to announce that, further to its news release of May 5, 2021, trading in the Company's common shares on the TSX Venture Exchange (the "TSXV") will commence at the opening of the market tomorrow, May 11, 2021, under the symbol "NICU". The commencement of trading follows the issuance of ...
Sky on Monday launched high-end TV series “Domina,” which examines Roman history through a female prism, toplining Kasia Smutniak (“Perfect Strangers,” “Devils”) as Livia Drusilla, the politically astute third wife of Emperor Augustus and mother of Emperor Tiberius, who managed to exert great power at a time of crisis for the Roman Empire. The Comcast-owned paybox […]
It’s been a long, strange trip in the four decades since Rick Doblin, a pioneering psychedelics researcher, dropped his first hit of acid in college and decided to dedicate his life to the healing powers of mind-altering compounds. Even as anti-drug campaigns led to the criminalization of Ecstasy, LSD and magic mushrooms, and drove most researchers from the field, Doblin continued his quixotic crusade with financial help from his parents. Doblin’s quest to win mainstream acceptance of psychedelics will take a significant leap forward Monday when the journal Nature Medicine is expected to publish the results of his lab’s study on MDMA, the club drug popularly known as Ecstasy and Molly. The study, the first Phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder. The results, coming weeks after a New England Journal of Medicine study that highlighted the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms, have excited scientists, psychotherapists and entrepreneurs in the rapidly expanding field of psychedelic medicine. They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically — for MDMA as soon as 2023, followed by psilocybin a year or two later. Sign up for The Morning newsletter from the New York Times After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction. The need for new therapeutics has gained greater urgency amid a national epidemic of opioid abuse and suicides. “Some days I wake up and can’t believe how far we’ve come,” said Doblin, 67, who now oversees the Multidisciplinary Association for Psychedelic Studies, a multimillion-dollar research and advocacy empire that employs 130 neuroscientists, pharmacologists and regulatory specialists working to lay the groundwork for the coming psychedelics revolution. The nation’s top universities are racing to set up psychedelic research centers, and investors are pouring millions of dollars into a pack of startups. States and cities across the country are beginning to loosen restrictions on the drugs, the first steps in what some hope will lead to the federal decriminalization of psychedelics for therapeutic and even recreational use. “There’s been a sea change in attitudes about what not long ago was considered fringe science,” said Michael Pollan, whose bestselling book on psychedelics, “How to Change Your Mind,” has helped destigmatize the drugs in the three years since it was published. “Given the mental health crisis in this country, there’s great curiosity and hope about psychedelics and a recognition that we need new therapeutic tools.” The question for many is how far — and how fast — the pendulum should swing, and even researchers who champion psychedelic-assisted therapy say the drive to commercialize the drugs combined with a growing movement to liberalize existing prohibitions could prove risky, especially for those with severe psychiatric disorders, and derail the field’s slow, methodical return to mainstream acceptance. Doblin’s organization, MAPS, is largely focused on winning approval for drug-assisted therapies and promoting them around the globe, but it is also pushing for the legalization of psychedelics at the federal level, though with strict licensing requirements for adult recreational use. Numerous studies have shown that classic psychedelics like LSD and psilocybin are not addictive and cause no organ damage in even high doses. And contrary to popular lore, Ecstasy does not leave holes in users’ brains, studies say, nor will a bad acid trip lead to chromosome damage. But most scientists agree that more research is needed on other possible side effects — like how the drugs might affect those with cardiac problems. And while the steady accumulation of encouraging data has softened the skepticism of prominent scientists, some researchers warn against the headlong embrace of psychedelics without stringent oversight. Although “bad trips” are rare, a handful of anecdotal reports suggest that psychedelics can induce psychosis in those with underlying mental disorders. Dr. Michael P. Bogenschutz, a professor of psychiatry who runs the 4-month-old Center for Psychedelic Medicine at NYU Langone Health, said most of the clinical studies to date had been conducted with relatively small numbers of people who were carefully vetted to screen out those with schizophrenia and other serious mental problems. That makes it hard to know whether there will be potential adverse reactions if the drugs are taken by millions of people without any guidance or supervision. “I know it sounds silly but, Kids, don’t take these at home,” Bogenschutz said. “I would just encourage everyone to not get ahead of the data.” The Rush to Invest Psychedelics are suddenly awash in money. Doblin can remember when research funding was nearly impossible to come by. But MAPS is flush now, having raised $44 million over the past two years. “I spend a lot of my time saying no to investors,” said Doblin, whose work has been funded by an unlikely collection of philanthropists, among them Rebekah Mercer, the Republican political donor, and David Bronner, a liberal heir to the liquid soap company Dr. Bronners. Johns Hopkins, Yale, the University of California, Berkeley, and Mount Sinai Hospital in New York are among the institutions that have recently established psychedelic research divisions or are planning to do so, with financing from private donors. And scientists are conducting studies on whether psychedelics can be effective in treating everything from depression, autism and opioid addiction to anorexia and the anxieties experienced by the terminally ill. More than a dozen startups have jumped into the fray, and the handful of companies that have gone public are collectively valued at more than $2 billion. Field Trip Health, a 2-year-old Canadian company that trades on the New York Stock Exchange, has raised $150 million to finance dozens of high-end ketamine clinics in Los Angeles, Chicago, Houston and other cities across North America. Compass Pathways, a health care company that has raised $240 million and is listed on the Nasdaq, is conducting 22 clinical trials across 10 countries of psilocybin therapy for treatment-resistant depression. Investors have been encouraged by the changing politics, a shift inspired in part by the nation’s accelerating embrace of recreational marijuana and by public weariness over America’s endless war on drugs. Last year, Oregon became the first state to legalize the therapeutic use of psilocybin. Denver, Oakland, California, and Washington, D.C. have decriminalized the drug, and several states, including California, are mulling similar legislation. Though the drugs remain illegal under federal law, the Justice Department has so far taken a hands-off approach to enforcement, similar to how it has handled recreational marijuana. Even some Republicans, a group that has traditionally opposed the liberalization of drug laws, are starting to come around. Last month, former Texas Gov. Rick Perry, citing the high rates of suicide among war veterans, called on his state’s legislators to support a Democratic-sponsored bill that would establish a psilocybin study for patients with PTSD. “We’ve had 50 years of government propaganda around these substances, and thanks to the research and a grassroots movement, that narrative is changing,” said Kevin Matthews, a psilocybin advocate who led Denver’s successful ballot measure. Decades in the Wilderness Long before Nancy Reagan warned the nation to just say no to drugs and President Richard Nixon supposedly pronounced Timothy Leary “the most dangerous man in America,” researchers like William A. Richards were using psychedelics to help alcoholics go dry and cancer patients cope with end-of-life anxiety. The drugs were legal, and Richards, then a psychologist at the Maryland Psychiatric Research Center, was among scores of scientists studying the therapeutic prowess of entheogens, the class of psychoactive substances that humans have used for millenniums. Even years later, Richards and other researchers say, many early volunteers called the psychedelic sessions the most important and meaningful experiences of their lives. But as the drugs left the lab in the 1960s and were embraced by the counterculture movement, the country’s political establishment reacted with alarm. By the time the Drug Enforcement Administration issued its emergency ban on MDMA in 1985, funding for psychedelic research had largely disappeared. “We were learning so much, and then it all came to an end,” said Richards, 80, now a researcher at Johns Hopkins University School of Medicine. These days, the Center for Psychedelic and Consciousness Research at Johns Hopkins, created two years ago with $17 million in private funding, is studying, among other things, psilocybin for smoking cessation and the treatment of depression associated with Alzheimer’s as well as more spiritual explorations involving religious clergy. “We have to be careful not to overpromise, but these are fantastically interesting compounds with numerous possible uses,” said Roland R. Griffiths, the center’s founding director and a psychopharmacologist whose 2006 study, on which he is a co-author with Richards, administered psilocybin to healthy volunteers — one of the first psychedelic studies to win FDA approval in a generation. Though researchers are still trying to understand the cognitive and therapeutic mechanics of psychedelics, they have concluded that psilocybin, DMT and other psychoactive chemicals can help people feel more tolerance, understanding and empathy. They also induce neuroplasticity, the brain’s ability to change and reorganize thought patterns, enabling people with psychological disorders to find new ways to process anxiety, depression or deeply embedded trauma. “They can help people who have lost the plotline of their lives,” Doblin said. The Trip Business The future of psychedelic medicine can already be glimpsed at a suite of plush, soothingly decorated “journey rooms” that occupy the top floor of an office building in Midtown Manhattan. The clinic, run by Field Trip Health, is a year-old venture where patients wear eyeshades and listen to electronic music and Tibetan chanting, as they are administered six ketamine injections over the course of several weeks. The 90-minute trips are interspersed with therapist-guided “integration sessions” to help participants process their experiences and work on achieving their mental health goals. A typical course of four sessions starts at $4,100, though some insurance companies reimburse patients for a portion of the cost. Ketamine is not a classic psychedelic; it is an anesthetic perhaps best known as both a club drug and a horse tranquilizer. But at higher doses, it can produce hallucinations, and it has shown promise treating major depression and severe PTSD, though the effects tend to be less enduring than therapies with psilocybin or MDMA. Ketamine, however, has a distinct advantage over those other drugs: It is the only one in the United States that is legally available to patients outside a clinical study. Emily Hackenburg, Field Trip’s clinical director, said the drug was only one component of a demanding therapeutic process. “The drug is not a magic bullet,” she said. Joe, a marketing executive in his mid-40s who has battled depression and anxiety for decades, said he decided to visit the company’s Atlanta location after seeing one of its ads on Facebook. Antidepressants, he said, left him emotionally brittle, and his years of psychotherapy were of little use. (He asked that his full name be withheld, citing the stigmas surrounding both mental illness and mind-altering drugs.) In an interview one week after his final session, he described a newfound awareness of the factors that could drive him to despair: his “alpha male” obsession with success, the frustrations stoked by his 9-year-old daughter’s misbehavior and the poor eating and drinking habits that often leave him feeling unwell. In a follow-up conversation two weeks later, Joe said the therapy’s effects were beginning to fade. He said that he was eager to try psilocybin-assisted therapy. “I’m really looking forward to the day when that becomes legal,” he said. So, too, is Field Trip. The company, which got its start opening cannabis clinics across Canada, is planning to test psilocybin therapy next month in Amsterdam, where magic mushroom truffles are legal. And its scientists are currently developing a new psychedelic that carries the therapeutic punch of psilocybin but works in about half the time — about two to three hours. Creating a proprietary short-lived psychedelic would reduce the staffing costs of supervised sessions, but more important, it would give the company lucrative exclusivity over its new drug. Other biotech companies are also developing new psychedelic compounds. Ronan Levy, Field Trip's executive chairman, said the company was hoping to grab a slice of the $240 billion that Americans spend each year on mental health services. “We are riding the forefront of what I think is going to be a significant cultural and business wave,” he said. To veteran scientists who lived through the nation’s earlier star-crossed love affair with psychedelics, such corporate boosterism is both thrilling and troubling. They are mindful about potential missteps that could undo the progress of recent years, and they question whether the coming commercialization could limit access to those with limited financial means. Dr. Charles S. Grob, a professor of psychiatry at UCLA’s school of medicine who has spent decades researching hallucinogens, worries that commercialization and a rush toward recreational use could prompt a public backlash, especially if increased availability of the drugs leads to a wave of troubling psychotic reactions. What is needed, he said, are rigorous protocols and a system to train and credential psychedelic medicine professionals. “We have to be very attentive to safety parameters, because if conditions are not properly maintained, there is a risk for some people to go off the rails psychologically,” he said. “And if the primary motivator is extracting profit, I feel the field is more vulnerable to mishaps.” Doblin shares some of those concerns, even if his institute stands to profit handsomely. Although MAPS is a nonprofit, it has recently created a corporate entity and hired management consultants to help plot the future of legalized MDMA therapy. Winning FDA approval would give MAPS at least six years of exclusivity to market its MDMA-guided treatments for PTSD, with a potential windfall of $750 million. Most of that money, he said, would help train a generation of psychedelic practitioners, fund lobbying efforts to require insurance coverage for such treatments and promote new therapies around the world. “Our goal is mass mental health,” he said, explaining the organization’s rejection of private investment. “It’s not to amass a whole bunch of money.” Despite his optimism, Doblin is not blind to the possibility that society’s fascination with psychedelics could sour. “We’ve made so much progress so fast but there are so many challenges ahead,” he said. “I realize,” he said, “we could screw things up at the last minute so I’m not planning to celebrate any time soon.” This article originally appeared in The New York Times. © 2021 The New York Times Company
New York , May 10, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Numinus Wellness Inc (CVE:NUMI) congratulates study team on announcement of results from Phase 3 randomized clinical trial of MDMA-assisted therapy for treatment of severe PTSD click hereAlpine 4 Holdings Inc (OTCQB:ALPP) says holding subsidiary enters nutraceutical and CBD manufacturing industry with acquisition of Alternative Labs click hereLucky Minerals Inc (CVE:LKY) (OTCMKTS:LKMNF) (FRA:LKY) says it has received the balance of assays from the initial prospecting at Wayka in Ecuador click hereDeep-South Resources Inc (CVE:DSM) (OTCMKTS:DSMTF) reveals first results from 10,000 metre drill program at flagship Haib copper project in Namibia click hereRidgeline MineralsCorp (CVE:RDG) (OTCQB:RDGMF) executes surface access agreement for its Bell Creek property with Nevada Gold Mines click hereVictory Square Technologies Inc (CSE:VST) (OTC:VSQTF) (FWB:6F6) trumpets US expansion of portfilio telemedicine comapny IV Hydreight Inc click hereFSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) files New Animal Drug Application with FDA for FSD201 to treat gastrointestinal enteropathy in dogs click hereOrganic Garage Ltd (CVE:OG) (OTCQX:OGGFF) adds another partner to its Hand-Picked retail program with Toronto's Cheese Boutique click herePlantX Life Inc (CSE:VEGA) (FRA:WNT1) (OTCQB:PLTXF) closes transaction to acquire privately-held cold-pressed juice maker, Little West click hereGoviEx Uranium Inc (CVE:GXU) (OTCQB:GVXXF) (FRA:7GU) says it “warmly welcomes” the reinstatement of its Chirundu mining license in Zambia click herePlaygon Games Inc (CVE:DEAL) (OTCQB:PLGNF) (FRA:7CR) says its live dealer casino platform Vegas Lounge now live with SWINNT click hereIpsidy Inc (OTCQB:IDTY) says its biometric identity verification services will be integrated into BPSmart’s chatbot platform click hereArcadia Biosciences Inc (NASDAQ:RKDA) says Belinda Yao has joined the company as vice president of operations click hereWIllow Biosciences Inc (TSE:WLLW) (OTCQX:CANSF) (FRA:3D7) ends 1Q with C$46.5M as it looks to its first CBG sales in 2Q click hereImagineAR Inc (CSE:IP) (OTCQB:IPNFF) (FRA:GMS1) secures seventh US patent; sees client activity ramp up in latest corporate update click hereElse Nutrition Holdings Inc (CVE:BABY) (OTCMKTS:BABY) (FRA:0YL) to offer its plant-based Complete Nutrition drink for toddlers in Haggen Food and Pharmacy stores in Washington State click hereFansUnite Entertainment Inc (CSE:FANS) (OTCQB:FUNFF) (FRA:4UY) integrates CoinsPaid cryptocurrency payments into its online gambling products click hereVanstar Mining Resources Inc (CVE:VSR) reveals that IAMGOLD poised to begin drilling at Nelligan project in June click hereBraxia Scientific Corp (CSE:BRAX) (FRA:496) (OTCQB:SHRMF) rebrands its psychedelic research and treatment clinics for mental disorders to Braxia Health click hereReal Luck Group Ltd (CVE:LUCK) says Thomas Rosander, formerly its chief customer officer, has been promoted to chief executive officer click hereVuzix Corporation (NASDAQ:VUZI) (FRA:V7XN) reports follow-on order of Blade Smart Glasses for Medacta's NextAR surgical platform click hereSilver Range Resources Ltd (CVE:SNG) (OTCMKTS:SLRRF) (FRA:8SR) samples up to 80 g/t gold at Cambridge Project in Nevada click here About Proactive With six offices on three continents and a team of experienced business journalists and broadcasters, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives engage intelligently with investors. Proactive’s platform delivers the right message to the right audience, digitally and in real time, leveraging a range of media, investment research, digital investor targeting and website development services to support over 1,000 fast-growing companies globally. Proactive’s network reaches over 12 million engaged private, professional and institutional investors looking for opportunities. • Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month. • We syndicate our content to hundreds of mainstream and specialist news sites that expand our reach into networks that can be difficult for press releases to penetrate. • We custom build corporate websites from the ground up, empowering clients and their brands with a modern online presence and the latest insight on effective SEO strategy • Our news coverage ranks high on the world’s most popular search platforms, and we can further amplify online presence and outreach with sophisticated digital investor targeting. • We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts. For more information on how Proactive can help you make a difference, email us at firstname.lastname@example.org